Bispecific antibodies are gaining widespread adoption thanks to a multi-pronged approach which has proven to be a powerful tool against intractable targets. Oncology is the best example where bispecific antibodies employ novel functionality for efficacy that is vastly improved over existing approaches. This meeting will review preclinical and clinical data and investigate tools and strategies for advancing molecules to the clinic.


KEYNOTE PRESENTATION: Clinical Progress in the Development of Immunotherapy for Advanced Cancer: Focus on Targeted Therapy Combinations

Jason J. Luke, M.D., FACP, Assistant Professor, Medicine, Hematology/Oncology, University of Chicago

Phase I Dose Escalation Study of MEDI-573, a Bispecific, Anti-Ligand Monoclonal Antibody against IGF-I and IGF-II in Patients with Advanced Solid Tumors

Paul Haluska, M.D., Ph.D., Co-Director, Phase I Program, Oncology, Mayo Clinic

Improving Cancer Treatment through Combination Immunotherapy

Holbrook E. Kohrt, M.D., Ph.D., Assistant Professor, Oncology, Stanford University

GBR1302-BEAT® Bispecific Antibody for the Treatment of HER2 Positive Cancers

Darko Skegro, Ph.D., Team Leader and Head, Bispecific Antibodies, Protein Engineering, Glenmark Pharmaceuticals

Ocular Targets

Justin M. Scheer, Ph.D., Senior Scientist, Protein Chemistry, Genentech

Talk Title to be Announced

Robert Wilkinson, Ph.D., Director, Oncology Research, MedImmune Ltd.

Controlled Fab-Arm Exchange for the Generation of Stable Bispecific IgG1

Paul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Genmab


Newest Results with Multifunctional ADCs

Zhenwei (David) Miao, Ph.D., CTO, Sorrento Therapeutics

Talk Title to be Announced

Peter A. Kiener, Ph.D., CSO, Ambrx, Inc.

Dual-Targeting Triplebodies for the Elimination of Leukemic Blasts and Leukemia Stem Cells

Georg H. Fey, Ph.D., Professor Emeritus, Biology, University of Erlangen-Nuremberg

Bispecific Approaches for Immunotherapy Using DART Technology

Scott Koenig, M.D., Ph.D., President, CEO & Director, Macrogenics, Inc.

Targeting Solid Tumors with a Multispecific ADC Approach

John Li, Ph.D., Scientist, Research, MedImmune

For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5464

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471